glutathione mutations in sclc patients NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced synthesis | EMBO Reports Glutathione Depletion and Stalwart Anticancer
Glutathione Depletion and Stalwart Anticancer Activity of Metallotherapeutics Inducing Programmed Cell Death: Opening a New Window for Cancer Therapy ACS Omega JCI Suppression of the SLC7A11 glutathione axis causes synthetic lethality in KRAS mutant lung adenocarcinoma Differential KEAP1 NRF2 mediated signaling widens the therapeutic window of redox targeting drugs in SCLC therapy Nature Communications Immunotherapy in small cell lung cancer: from molecular promises to clinical challenges Journal for ImmunoTherapy of Cancer Cell Death, Molecular Targeted Therapies, and Metabolic Reprogramming in EGFR Mutant Lung Cancer
Pay in 4 interest-free payments of $6.01 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3




